文献速递心血管胸部MRPET

心脏MRI与PET成像在心脏结节病诊断和监测中的更新

Updates on Cardiac MRI and PET Imaging for the Diagnosis and Monitoring of Cardiac Sarcoidosis.
PubMed 文献 · Korean J Radiol · 2025-01-01

心脏结节病临床表现异质且传统诊断手段有限,CMR与FDG-PET显著改变了其评估与管理。CMR的LGE、T1/T2 mapping及细胞外容积定量可无与伦比地显示心肌结构与纤维化,T2 mapping高值可靠提示急性活动性炎症;FDG-PET可检测活动性肉芽肿性炎症并指导免疫抑制治疗,两者协同可识别亚临床病变并优化治疗策略。

要点

  • T2 mapping高值可靠提示心脏结节病急性活动状态,为活动性炎症的标记。
  • CMR的LGE、T1/T2 mapping及细胞外容积定量可评估心肌结构与纤维化,并提示疾病活动与治疗反应。
  • FDG-PET检测活动性肉芽肿性炎症,与CMR协同可识别亚临床病变并指导免疫抑制治疗。

核心结论

  • CMR与FDG-PET的协同整合为心脏结节病的诊断和监测提供了全面方法,可识别亚临床病变并优化治疗策略,定量生物标志物(如应变指标和T2值)有望进一步细化疾病评估与管理。

研究设计与样本

  • 综述,汇总心脏磁共振(CMR)与¹⁸F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)在心脏结节病诊断和监测中的进展。

关键影像表现/征象

  • CMR凭借更优的空间分辨率及晚期钆增强、T1/T2 mapping和细胞外容积定量等技术,提供心肌结构与纤维化的深入信息。
  • T2 mapping高值可靠指示急性疾病状态,为活动性炎症的有价值标记。
  • FDG-PET可检测活动性肉芽肿性炎症,并指导免疫抑制治疗。

诊断标准与关键数值

  • T2 mapping高值可靠指示急性疾病状态。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Cardiac sarcoidosis (CS) poses significant diagnostic and therapeutic challenges due to its heterogeneous clinical manifestations and the limitations of conventional diagnostic approaches. Advances in imaging modalities, particularly cardiac magnetic resonance imaging (CMR) and ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET), have revolutionized the evaluation and management of this complex condition. CMR, with its superior spatial resolution and advanced techniques such as late gadolinium enhancement, T1/T2 mapping, and extracellular volume quantification, offers unparalleled insights into myocardial structure and fibrosis. These techniques not only enhance diagnostic accuracy but also provide critical information on disease activity and treatment response. Among these, T2 mapping has emerged as a valuable marker for active inflammation, with high values reliably indicating acute disease states. FDG-PET serves as a complementary modality by detecting active granulomatous inflammation and guiding immunosuppressive therapy. The synergistic integration of CMR and FDG-PET provides a comprehensive approach to diagnosing and monitoring CS, enabling the identification of subclinical disease and the optimization of therapeutic strategies. Furthermore, the incorporation of quantitative biomarkers, such as strain metrics and T2 values, promises to refine disease assessment and management. These advancements have the potential to transform the paradigm of CS care, ultimately improving patient outcomes.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Oyama-Manabe N, Manabe O, Aikawa T, et al. Updates on Cardiac MRI and PET Imaging for the Diagnosis and Monitoring of Cardiac Sarcoidosis. Korean J Radiol. 2025. PMID: 40873372. doi:10.3348/kjr.2025.0148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。